07:29 AM EDT, 04/23/2024 (MT Newswires) -- Specialty life sciences company Revive Therapeutics ( RVVTF ) on Tuesday reported that the US FDA has granted the company's request for a Type C Meeting, to evaluate a proposed clinical study of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.

The meeting date is June 9, 2024.

The Centre for Disease Control and Prevention estimates that 7.5% of US adults have long COVID symptoms.